

Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/E8F4970521CAEN.html>

Date: November 2024

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: E8F4970521CAEN

Abstracts

This report can be delivered to the clients within Immediate

Erectile Dysfunction Drugs Market Growth & Trends

The global erectile dysfunction drugs market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.

Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products

in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.

Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan HaiscPharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Stendra's (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.

Erectile Dysfunction Drugs Market Report Highlights

By product, the Viagra segment held the largest market share in 2024 due to the worldwide availability of Viagra and increased awareness about the product among ED patients

North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 50.54% in 2024, due to the high burden of disease, strong healthcare infrastructure, and rapid approval of new products for treatment in the region.

The oral mode segment accounted for the largest market share of 84.03% in 2024. The oral mode of administration is a dominant segment in the market, driven by its convenience, non-invasive nature, and widespread patient preference

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
 - 1.2.1. Product
 - 1.2.2. Mode of Administration
 - 1.2.3. Regional Scope
 - 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights

CHAPTER 3. ERECTILE DYSFUNCTION DRUGS MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.1.1. Increasing prevalence of erectile dysfunction
 - 3.2.1.2. Rising geriatric population
 - 3.2.1.3. Increasing research & development (R&D)
 - 3.2.2. Market Restraint Analysis
 - 3.2.2.1. Lack of healthcare infrastructure and manufacturing errors
 - 3.2.2.2. Lack of awareness about erectile dysfunction
- 3.3. Erectile Dysfunction Drugs Market Analysis Tools
 - 3.3.1. Industry Analysis - Porter's
 - 3.3.1.1. Bargaining power of suppliers
 - 3.3.1.2. Bargaining power of buyers
 - 3.3.1.3. Threat of substitutes
 - 3.3.1.4. Threat of new entrants
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Economic landscape
 - 3.3.2.3. Social landscape
 - 3.3.2.4. Technological landscape
 - 3.3.2.5. Environmental landscape
 - 3.3.2.6. Legal landscape

CHAPTER 4. ERECTILE DYSFUNCTION DRUGS MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. Erectile Dysfunction Drugs Market: Product Movement Analysis
- 4.3. Erectile Dysfunction Drugs Market by Product Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Viagra (sildenafil citrate)
 - 4.5.1. Viagra (sildenafil citrate) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Cialis (Tadalafil)
 - 4.6.1. Cialis (Tadalafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.7. Stendra/Spedra (avanafil)

4.7.1. Stendra/Spedra (avanafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.8. Zydena (udenafil)

4.8.1. Zydena (udenafil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.9. Other Drugs

4.9.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 5. ERECTILE DYSFUNCTION DRUGS MARKET: MODE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

5.1. Segment Dashboard

5.2. Erectile Dysfunction Drugs Market: Mode of Administration Movement Analysis

5.3. Erectile Dysfunction Drugs Market by Mode of Administration Outlook (USD Million)

5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following

5.5. Oral Mode of Administration

5.5.1. Oral Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

5.6. Injectable Mode of Administration

5.6.1. Injectable Mode of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

5.7. Other Modes of Administration

5.7.1. Other Modes of Administration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 6. ERECTILE DYSFUNCTION DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

6.1. Regional Dashboard

6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:

6.3. North America

6.3.1. U.S.

6.3.1.1. Key country dynamics

6.3.1.2. Regulatory framework/ reimbursement structure

6.3.1.3. Competitive scenario

6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

6.3.2. Canada

- 6.3.2.1. Key country dynamics
- 6.3.2.2. Regulatory framework/ reimbursement structure
- 6.3.2.3. Competitive scenario
- 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. Mexico
 - 6.3.3.1. Key country dynamics
 - 6.3.3.2. Regulatory framework/ reimbursement structure
 - 6.3.3.3. Competitive scenario
 - 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4. Europe
 - 6.4.1. UK
 - 6.4.1.1. Key country dynamics
 - 6.4.1.2. Regulatory framework/ reimbursement structure
 - 6.4.1.3. Competitive scenario
 - 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.4.2. Germany
 - 6.4.2.1. Key country dynamics
 - 6.4.2.2. Regulatory framework/ reimbursement structure
 - 6.4.2.3. Competitive scenario
 - 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.4.3. France
 - 6.4.3.1. Key country dynamics
 - 6.4.3.2. Regulatory framework/ reimbursement structure
 - 6.4.3.3. Competitive scenario
 - 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.4.4. Italy
 - 6.4.4.1. Key country dynamics
 - 6.4.4.2. Regulatory framework/ reimbursement structure
 - 6.4.4.3. Competitive scenario
 - 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.4.5. Spain
 - 6.4.5.1. Key country dynamics
 - 6.4.5.2. Regulatory framework/ reimbursement structure
 - 6.4.5.3. Competitive scenario
 - 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.4.6. Norway
 - 6.4.6.1. Key country dynamics
 - 6.4.6.2. Regulatory framework/ reimbursement structure
 - 6.4.6.3. Competitive scenario

- 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.7. Sweden
 - 6.4.7.1. Key country dynamics
 - 6.4.7.2. Regulatory framework/ reimbursement structure
 - 6.4.7.3. Competitive scenario
 - 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.4.8. Denmark
 - 6.4.8.1. Key country dynamics
 - 6.4.8.2. Regulatory framework/ reimbursement structure
 - 6.4.8.3. Competitive scenario
 - 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Asia Pacific
 - 6.5.1. Japan
 - 6.5.1.1. Key country dynamics
 - 6.5.1.2. Regulatory framework/ reimbursement structure
 - 6.5.1.3. Competitive scenario
 - 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.5.2. China
 - 6.5.2.1. Key country dynamics
 - 6.5.2.2. Regulatory framework/ reimbursement structure
 - 6.5.2.3. Competitive scenario
 - 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.5.3. India
 - 6.5.3.1. Key country dynamics
 - 6.5.3.2. Regulatory framework/ reimbursement structure
 - 6.5.3.3. Competitive scenario
 - 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.5.4. Australia
 - 6.5.4.1. Key country dynamics
 - 6.5.4.2. Regulatory framework/ reimbursement structure
 - 6.5.4.3. Competitive scenario
 - 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.5.5. South Korea
 - 6.5.5.1. Key country dynamics
 - 6.5.5.2. Regulatory framework/ reimbursement structure
 - 6.5.5.3. Competitive scenario
 - 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
 - 6.5.6. Thailand
 - 6.5.6.1. Key country dynamics

6.5.6.2. Regulatory framework/ reimbursement structure

6.5.6.3. Competitive scenario

6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

6.6. Latin America

6.6.1. Brazil

6.6.1.1. Key country dynamics

6.6.1.2. Regulatory framework/ reimbursement structure

6.6.1.3. Competitive scenario

6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

6.6.2. Argentina

6.6.2.1. Key country dynamics

6.6.2.2. Regulatory framework/ reimbursement structure

6.6.2.3. Competitive scenario

6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

6.7. MEA

6.7.1. South Africa

6.7.1.1. Key country dynamics

6.7.1.2. Regulatory framework/ reimbursement structure

6.7.1.3. Competitive scenario

6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

6.7.2. Saudi Arabia

6.7.2.1. Key country dynamics

6.7.2.2. Regulatory framework/ reimbursement structure

6.7.2.3. Competitive scenario

6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

6.7.3. UAE

6.7.3.1. Key country dynamics

6.7.3.2. Regulatory framework/ reimbursement structure

6.7.3.3. Competitive scenario

6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

6.7.4. Kuwait

6.7.4.1. Key country dynamics

6.7.4.2. Regulatory framework/ reimbursement structure

6.7.4.3. Competitive scenario

6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. COMPETITIVE LANDSCAPE

7.1. Market Participant Categorization

7.2. Recent Developments & Impact Analysis by Key Market Participants

7.3. Company Market Share Analysis, 2024

7.4. Key Company Profiles

7.4.1. Bayer AG

7.4.1.1. Company overview

7.4.1.2. Financial performance

7.4.1.3. Product benchmarking

7.4.1.4. Strategic initiatives

7.4.2. Lilly

7.4.2.1. Company overview

7.4.2.2. Financial performance

7.4.2.3. Product benchmarking

7.4.2.4. Strategic initiatives

7.4.3. GlaxoSmithKline PLC

7.4.3.1. Company overview

7.4.3.2. Financial performance

7.4.3.3. Product benchmarking

7.4.3.4. Strategic initiatives

7.4.4. Petros Pharmaceuticals, Inc.

7.4.4.1. Company overview

7.4.4.2. Financial performance

7.4.4.3. Product benchmarking

7.4.4.4. Strategic initiatives

7.4.5. Pfizer Inc.

7.4.5.1. Company overview

7.4.5.2. Financial performance

7.4.5.3. Product benchmarking

7.4.5.4. Strategic initiatives

7.4.6. Teva Pharmaceutical Industries Ltd

7.4.6.1. Company overview

7.4.6.2. Financial performance

7.4.6.3. Product benchmarking

7.4.6.4. Strategic initiatives

7.4.7. Lupin Limited

7.4.7.1. Company overview

7.4.7.2. Financial performance

7.4.7.3. Product benchmarking

7.4.7.4. Strategic initiatives

7.4.8. Futura Medical

- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. Cure Pharmaceutical
 - 7.4.9.1. Company overview
 - 7.4.9.2. Financial performance
 - 7.4.9.3. Product benchmarking
 - 7.4.9.4. Strategic initiatives
- 7.4.10. 23andMe
 - 7.4.10.1. Company overview
 - 7.4.10.2. Financial performance
 - 7.4.10.3. Product benchmarking
 - 7.4.10.4. Strategic initiatives
- 7.4.11. Hims & Hers Health, Inc.
 - 7.4.11.1. Company overview
 - 7.4.11.2. Financial performance
 - 7.4.11.3. Product benchmarking
 - 7.4.11.4. Strategic initiatives
- 7.4.12. RO
 - 7.4.12.1. Company overview
 - 7.4.12.2. Financial performance
 - 7.4.12.3. Product benchmarking
 - 7.4.12.4. Strategic initiatives
- 7.4.13. BlueChew
 - 7.4.13.1. Company overview
 - 7.4.13.2. Financial performance
 - 7.4.13.3. Product benchmarking
 - 7.4.13.4. Strategic initiatives
- 7.4.14. GoodRx, Inc.
 - 7.4.14.1. Company overview
 - 7.4.14.2. Financial performance
 - 7.4.14.3. Product benchmarking
 - 7.4.14.4. Strategic initiatives

I would like to order

Product name: Erectile Dysfunction Drugs Market Size, Share & Trends Analysis Report By Product (Viagra, Cialis, Levitra/Staxyn), By Mode of Administration (Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/E8F4970521CAEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E8F4970521CAEN.html>